APIXABAN TEVA®
(apixaban)
TEVA
HK Reg. No. HK-68762 (16 Jul, 2025)
Composition:4
• Each film-coated tablet contains 2.5 mg apixaban
Indication:4
• Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery
• Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (New York Heart Association [NYHA] Class ≥ II)
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
References
4. EMC. Apixaban 2.5mg Film-Coated Tablets Healthcare Professionals (SmPC). 19 March 2025. Available from: https://www.medicines.org.uk/emc/product/13686/smpc. [Accessed 18 July 2025].
